

Psychopharmacology

CONTENTS OF VOLUME 131 • 1997

For North and South America

For the rest of the world

Clinical psychopharmacology

Field editors D.E. Casey, Portland
W. Potter, Indianapolis

J. Gerlach, Roskilde
P.J. Cowen, Oxford

Advisory editors B. Cohen, Belmont
R. Poland, Torrance

P. Bech, Hillerød
W.F. Gattaz, São Paulo
O. Lingjaerde, Oslo
E.S. Paykel, Cambridge

Human cognitive psychopharmacology

Field editors H. de Wit, Chicago

D.M. Warburton, Reading

Advisory editors E. Gamzu, Cambridge
T. Roehrs, Detroit
B.J. Spring, North Chicago
H. Weingartner, Washington DC

I. Hindmarch, Guildford
B.J. Sahakian, Cambridge
K. Siegfried, Frankfurt

Alcohol and substance abuse in humans

Field editors H. de Wit, Chicago

D.M. Warburton, Reading

Advisory editors G. Bigelow, Baltimore
S.S. O'Malley, New Haven
K.A. Perkins, Pittsburgh

I. Hindmarch, Guildford
B.J. Sahakian, Cambridge
K. Siegfried, Frankfurt

Biochemical neuropharmacology, drug metabolism and pharmacokinetics

Field editors D.R. Sibley, Bethesda

J. Leysen, Beerse

Advisory editors I. Creese, Newark
I. Kopin, Bethesda
J.M. Perel, Pittsburgh

J. Heykants, Beerse
J. Hyttel, Copenhagen-Valby
C.A. Marsden, Nottingham
M.B.H. Youdim, Haifa

Behavioral pharmacology in laboratory animals

Field editors K.A. Miczek, Medford

T.W. Robbins, Cambridge

Advisory editors R.L. Balster, Richmond
J.E. Barrett, Princeton
J. Bergman, Southborough
K.A. Grant, Winston-Salem
S.G. Holtzman, Atlanta
H. Kalant, Toronto

A.R. Cools, Nijmegen
B.J. Everitt, Cambridge
A.J. Goudie, Liverpool
W. Koek, Castres
I.P. Stolerman, London
M.-H. Thiebot, Paris

Preclinical psychopharmacology

Field editors M.A. Geyer, La Jolla

A.R. Green, Loughborough

Advisory editors H.C. Fibiger, Vancouver, BC
S.D. Glick, Albany
G.F. Koob, San Diego
S.B. Sparber, Minneapolis
R.A. Wise, Montreal

G. Di Chiara, Cagliari
D.J. Heal, Nottingham
P. Jenner, London
H.J. Little, Durham
J.L. Waddington, Dublin 2

Psychopharmacology

This journal was founded as **Psychopharmacologia** in 1959 and was renamed **Psychopharmacology** beginning with Vol. 46 (1976).

The journal has been edited by the following Managing Editors:

Vol. 1 (1959), E. Rothlin and A. Wikler; Vol. 2 (1961), E. Rothlin and H. Isbell; Vol. 3 (1962), E. Rothlin and A. Wikler; Vol. 4 (1963)–Vol. 7 (1965), J.O. Cole and E. Rothlin; Vol. 8 (1965)–Vol. 16 (1969), J.O. Cole, E. Jacobsen, M.E. Jarvik, M. Shepherd; Vol. 17 (1970), J.O. Cole, E. Jacobsen, C. Kornetzky, M. Shepherd; Vol. 18 (1970)–Vol. 27 (1972), J.O. Cole, M. Hamilton, E. Jacobsen, C. Kornetzky; Vol. 28 (1973)–Vol. 35 (1974), J.O. Cole, M. Hamilton, E. Jacobsen, C. Kornetzky, R.W. Russell; Vol. 36 (1974)–Vol. 69 (1980), H. Barry III, J.O. Cole, M. Hamilton, E. Jacobsen, R.W. Russell; Vol. 70 (1980)–Vol. 77 (1982), H. Barry III, J.O. Cole, M. Hamilton, T.W. Robbins, R.W. Russell.

Starting with Vol. 80 (1983) the Editors have been: H. Barry III, T.W. Robbins (Coordinating Editors), J.O. Cole, J. Gerlach, M. Hamilton, J. Leysen, F. Sulser. As of Vol. 85 (1985): H. Barry III, D.E. Casey, J.O. Cole, J. Gerlach, S.D. Glick, A.R. Green, M. Hamilton, J. Leysen, T.W. Robbins, F. Sulser. As of Vol. 92 (1987): H. Barry III, D.E. Casey, J. Gerlach, S.D. Glick, A.R. Green, J. Leysen, T.W. Robbins, B.J. Spring, F. Sulser, D.M. Warburton. As of Vol. 98 (1989): H. Barry III, D.E. Casey, J. Gerlach, S.D. Glick, A.R. Green, J. Leysen, T.W. Robbins, D.R. Sibley, B.J. Spring, D.M. Warburton. As of Vol. 106 (1992): D.E. Casey, J. Gerlach, M.A. Geyer, A.R. Green, J. Leysen, K.A. Miczek, T.W. Robbins, D.R. Sibley, B.J. Spring, D.M. Warburton. As of Vol. 109 (1992): D.E. Casey, J. Gerlach, M.A. Geyer, A.R. Green, J. Leysen, K.A. Miczek, T.W. Robbins, D.R. Sibley, B.J. Spring, D.M. Warburton, H. de Wit. As of Vol. 117 (1995): D.E. Casey, J. Gerlach, M.A. Geyer, A.R. Green, J. Leysen, K.A. Miczek, T.W. Robbins, D.R. Sibley, D.M. Warburton, H. de Wit.

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made.

The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA: Photocopies may be made for personal or in-house use beyond the limitations stipulated under Section 107 or 108 of U.S. Copyright Law, provided a fee is paid. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0033-3158, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

The Canada Institute for Scientific and Technical Information (CISTI) provides a comprehensive, world-wide document delivery service for all Springer-Verlag journals. For more information, or to place an order for a copyright-cleared Springer-Verlag document, please contact Client Assistant, Document Delivery, Canada Institute for Scientific and Technical Information, Ottawa K1A 0S2, Canada, Tel. (613) 993-9251, FAX (613) 952-8243, e-mail: cisti.docdel@nrc.ca

ADONIS Identification System

The journal *Psychopharmacology* appears twice a month. It is published by Springer-Verlag Berlin, Heidelberger Platz 3, D-14197 Berlin. This journal is included in the ADONIS service, whereby copies of individual articles can be printed out from compact discs (CD-ROM) on demand. An explanatory leaflet giving further details of the scheme is available from the publishers on request.

Journals Preview Service

This journal is included in the Springer Journals Preview Service, i.e. the tables of contents and BiblioAbstracts are available via Internet before the new issue reaches the subscribers. Tables of contents are free of charge; BiblioAbstracts are available for a small annual fee. Details can be obtained by sending an e-mail message containing the line help to svjps@springer.de

Printers

Universitätsdruckerei H. Stürtz AG,
Würzburg, Germany

Publisher

© Springer-Verlag Berlin Heidelberg 1997
Springer-Verlag GmbH & Co. KG Berlin,
Germany

Printed in Germany



Springer

Contents of Volume 131 · 1997

- Abe Y → Kudo S
Akashi K → Morioka C
Andreassen OA, MacEwan T, Gulbrandsen A-K, McCreadie RG, Steen VM: Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients 174
Andrée B, Halldin C, Vrijmoed-de Vries M, Farde L: Central 5-HT_{2A} and D₂ dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men 339
Andrews MM → Roberts DCS
Anton RF, Kranzler HR, McEvoy JP, Moak DH, Bianca R: A double-blind comparison of abecarnil and diazepam in the treatment of uncomplicated alcohol withdrawal 123
Apfelbaum JL → Conley KM
ARCS Study Group → Jeste DV
Balcels-Oliviero M, Vezina P: Effects of naltrexone on amphetamine-induced locomotion and rearing: acute and repeated injections 230
Bannerjee A → Elliott R
Baumann MH → Shoaib M
Bell SM, Stewart RB, Thompson SC, Meisch RA: Food-deprivation increases cocaine-induced conditioned place preference and locomotor activity in rats 1
Bianca R → Anton RF
Biggio G → Motzo C
Blanco-Centurion C → Salin-Pascual RJ
Bonhomme N → Lucas G
Boone KB → Poland RE
Borg S → Saxon L
Bourin M → Volk V
Brammer GL → Poland RE
Brecher M → Jeste DV
Breese GR → Moy SS
Byrd LD → Howell LL
Carter DB → Tang AH
Casal L → Krystal JH
Charney DS → Krystal JH
Clyde C → Jeste DV
Compaan JC → Groenink L
Conley KM, Toledano AY, Apfelbaum JL, Zacny JP: Modulating effects of a cold water stimulus on opioid effects in volunteers 313
Conway SC → Goodwin GM
Cooney N → Krystal JH
Cooper SJ → Higgs S
Costall B → Smith JK
Criswell HE → Moy SS
Czoty PW → Howell LL
Danion JM → Peretti CS
Davis M → Krystal JH
Dazzi L → Motzo C
De Deurwaerdere P → Lucas G
De Vries TJ → Vanderschuren LJMJ
Deuschle M, Härtter S, Hiemke C, Standhardt H, Heuser I: Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients 19
Dewey SL → Ding Y-S
Ding Y-S, Fowler JS, Volkow ND, Dewey SL, Wang G-J, Logan J, Gatley SJ, Pappas N: Chiral drugs: comparison of the pharmacokinetics of [¹¹C]d-threo and l-threo-methylphenidate in the human and baboon brain 71
D'Amico D → Perkins KA
Drucker-Colin R → Salin-Pascual RJ
Ebmeier KP → Goodwin GM
Ellinwood EHJr → Hege SG
Elliott R, Sahakian BJ, Matthews K, Bannerjee A, Rimmer J, Robbins TW: Effects of methylphenidate on spatial working memory and planning in healthy young adults 196
Erp AMM van, Miczek KA: Increased aggression after ethanol self-administration in male resident rats 287
Ettenberg A → McFarland K
Farde L → Andrée B
Field MJ → Rupniak NMJ
Fowler JS → Ding Y-S
France CP → Gerak LR
Franklin SR → Tang AH
Furukawa M → Kudo S
Furukawa T → Morioka C
García-Ferreiro R → Salin-Pascual RJ
Gatley SJ → Ding Y-S
Gerak LR, France CP: Repeated administration of flumazenil does not alter its potency in modifying schedule-controlled behavior in chlordiazepoxide-treated rhesus monkeys 64
Glabus MF → Goodwin GM
Goldberg SR → Shoaib M
Goldman NH → Rush CR
Goodwin GM, Conway SC, Peyro-Saint-Paul H, Glabus MF, O'Carroll RE, Ebmeier KP: Executive function and uptake of ^{99m}Tc-exametazime shown by single photon emission tomography after oral idazoxan in probable Alzheimer-type dementia 371
Graham SM → Hege SG
Grangé D → Peretti CS
Griebel G, Perrault G, Sanger DJ: Behavioural profiles of the reversible monoamine-oxidase-A inhibitors belfoxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs 180
Grillon C → Krystal JH
Grob CS → Poland RE
Groenink L, Van der Gugten J, Compaan JC, Maes RAA, Olivier B: Flesinoxan pretreatment differentially affects corticosterone, prolactin and behavioural responses to a flesinoxan challenge 93
Gulbrandsen A-K → Andreassen OA
Halldin C → Andrée B
Härtter S → Deuschle M
Hayes CA → Rush CR
Hege SG, Ellinwood EHJr, Wilson WH, Helligers CAM, Graham SM: Psychomotor effects of the anxiolytic abecarnil: a comparison with lorazepam 101
Helligers CAM → Hege SG
Hernández LL, Watson KL: Opioid modulation of attention-related responses: delta-receptors modulate habituation and conditioned bradycardia 140
Heuser I → Deuschle M
Hiemke C → Deuschle M
Higashima M, Kinoshita H, Yamaguchi N, Koshino Y: Differences in enhancing effects of zolpidem and benzodiazepine drugs on recurrent inhibition in rat hippocampal slices 394
Higgs S, Cooper SJ: Midazolam-induced rapid changes in licking behaviour: evidence for involvement of endogenous opioid peptides 278
Hiltunen AJ → Saxon L
Hinchliffe RM → Woodruff-Pak DS
Hitchcott PK, Phillips GD: Amygdala and hippocampus control dissociable aspects of drug-associated conditioned rewards 187
Hjemdahl P → Saxon L
Houle S → Kapur S
Howell LL, Czoty PW, Byrd LD: Pharmacological interactions between serotonin and dopamine on behavior in the squirrel monkey 40
Jackson DM → Johansson C
Jacobsen EJ → Tang AH
Jeste DV, Klausner M, Brecher M, Clyde C, Jones R, ARCS Study Group: A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial 239
Johansson C, Jackson DM, Svensson L: Nitric oxide synthase inhibition blocks phencyclidine-induced behavioural effects on prepulse inhibition and locomotor activity in the rat 167
Johnson CA → Rush CR
Jones C → Kapur S
Jones R → Jeste DV
Kaneko T, Thompson RF: Disruption of trace conditioning of the nictitating membrane response in rabbits by central cholinergic blockade 161
Kapur S, Zipursky R, Roy P, Jones C, Remington G, Reed K, Houle S: The relationship between D₂ receptor occupancy and plasma levels on low dose oral haloperidol: a PET study 148
Kauffmann-Muller F → Peretti CS
Kemppainen S → Riekkinen M
Kikuchi T, Uwahodo Y, Tottori K, Nakai M, Morita S: The attenuating effect of carterol hydrochloride, a β -adrenoceptor antagonist, on neuroleptic-induced catalepsy in rats 108
Kinoshita H → Higashima M
Klausner M → Jeste DV

- Kleven MS, Koek W: Discriminative stimulus properties of cocaine: enhancement by β -adrenergic receptor antagonists 307
- Knapp DJ \rightarrow Moy SS
- Koek W \rightarrow Kleven MS
- Köks S \rightarrow Volke V
- Kondo H \rightarrow Morioka C
- Koshino Y \rightarrow Higashima M
- Kranzler HR \rightarrow Anton RF
- Krystal JH, Webb E, Grillon C, Cooney N, Casal L, Morgan III CA, Southwick SM, Davis M, Charney DS: Evidence of acoustic startle hyperreflexia in recently detoxified early onset male alcoholics: modulation by yohimbine and *m*-Chlorophenylpiperazine (mCPP) 207
- Kudo S, Umehara K, Abe Y, Furukawa M, Odomi M: Intracerebral penetration of carbetolol hydrochloride in rats 388
- Le Moal M \rightarrow Lucas G
- Lee MD, Simansky KJ: CP-94,253: a selective serotonin_{1B} (5-HT_{1B}) agonist that promotes satiety 264
- Livermore CL \rightarrow Nation JR
- Logan J \rightarrow Ding Y-S
- Lucas G, Bonhomme N, De Deurwaerdere P, Le Moal M, Spampinato U: 8-OH-DPAT, a 5-HT_{1A} agonist and ritanserin, a 5-HT_{2AC} antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release 57
- Lutchmansingh P \rightarrow Poland RE
- MacEwan T \rightarrow Andreassen OA
- Madakasira S \rightarrow Rush CR
- Maes RAA \rightarrow Groenink L
- Makinaga G \rightarrow Morioka C
- Maldonado R \rightarrow Valverde O
- Männistö PT \rightarrow Volke V
- Marsden CA \rightarrow Mongeau R
- Matsumura K \rightarrow Morioka C
- Matthews K \rightarrow Elliott R
- McCracken JT \rightarrow Poland RE
- McCreddie RG \rightarrow Andreassen OA
- McEvoy JP \rightarrow Anton RF
- McFarland K, Ettenberg A: Reinstatement of drug-seeking behavior produced by heroin-predictive environmental stimuli 86
- Meisch RA \rightarrow Bell SM
- Miczek KA \rightarrow Erp AMM van
- Miller DK \rightarrow Nation JR
- Misawa M \rightarrow Suzuki T
- Moak DH \rightarrow Anton RF
- Mongeau R, Marsden CA: Effect of imipramine treatments on the 5-HT_{1A}-receptor-mediated inhibition of panic-like behaviours in rats 321
- Morgan III CA \rightarrow Krystal JH
- Mori T \rightarrow Suzuki T
- Morioka C, Kondo H, Akashi K, Matsumura K, Ochi N, Makinaga G, Furukawa T: The continuous and simultaneous blood flow velocity measurement of four cerebral vessels and a peripheral vessel during cigarette smoking 220
- Morita S \rightarrow Kikuchi T
- Moro-López ML \rightarrow Salín-Pascual RJ
- Motzo C, Porceddu ML, Dazzi L, Sanna A, Serra M, Biggio G: Enhancement by flumazenil of dopamine release in the nucleus accumbens of rats repeatedly exposed to diazepam or imidazenil 34
- Moy SS, Knapp DJ, Criswell HE, Breese GR: Flumazenil blockade of anxiety following ethanol withdrawal in rats 354
- Mulder AH \rightarrow Vanderschuren LJM
- Nakai M \rightarrow Kikuchi T
- Nation JR, Miller DK, Livermore CL: Chronic exposure to cadmium attenuates behavioral sensitization to morphine 248
- Needham LM \rightarrow Tang AH
- Neill JC \rightarrow Smith JK
- Nestby P \rightarrow Vanderschuren LJM
- Ochi N \rightarrow Morioka C
- Odomi M \rightarrow Kudo S
- Olivier B \rightarrow Groenink L
- Onodera K \rightarrow Suzuki T
- O'Carroll RE \rightarrow Goodwin GM
- Pappas N \rightarrow Ding Y-S
- Patat A \rightarrow Peretti CS
- Pazzaglia PJ \rightarrow Rush CR
- Pechnick RN \rightarrow Poland RE
- Peretti CS, Danion JM, Kauffmann-Muller F, Grangé D, Patat A, Rosenzweig P: Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers 329
- Perkins KA, Sanders M, D'Amico D, Wilson A: Nicotine discrimination and self-administration in humans as a function of smoking status 361
- Perrault G \rightarrow Griebel G
- Peyro-Saint-Paul H \rightarrow Goodwin GM
- Phillips GD \rightarrow Hitchcott PK
- Poland RE, Lutchmansingh P, McCracken JT, Zhao J-P, Brammer GL, Grob CS, Boone KB, Pechnick RN: Abnormal ACTH and prolactin responses to fenfluramine in rats exposed to single and multiple doses of MDMA 411
- Porceddu ML \rightarrow Motzo C
- Reed K \rightarrow Kapur S
- Remington G \rightarrow Kapur S
- Riekkinen M, Kemppainen S, Riekkinen P Jr: Effects of stimulation of α_1 -adrenergic and NMDA/glycine-B receptors on learning deficits in aged rats 49
- Riekkinen P Jr \rightarrow Riekkinen M
- Rimmer J \rightarrow Elliott R
- Robbins TW \rightarrow Elliott R
- Roberts DCS, Andrews MM: Baclofen suppression of cocaine self-administration: demonstration using a discrete trials procedure 271
- Roques BP \rightarrow Valverde O
- Rosenzweig P \rightarrow Peretti CS
- Rothman RB \rightarrow Shoaib M
- Roy P \rightarrow Kapur S
- Rupniak NMJ, Tye SJ, Field MJ: Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys 406
- Rush CR, Madakasira S, Hayes CA, Johnson CA, Goldman NH, Pazzaglia PJ: Trazodone and triazolam: acute subject-rated and performance-impairing effects in healthy volunteers 9
- Sahakian BJ \rightarrow Elliott R
- Salín-Pascual RJ, García-Ferreiro R, Moro-López ML, Blanco-Centurión C, Drucker-Colín R: Repeated REM sleep deprivation after chronic haloperidol administration in the rat 216
- Sanders M \rightarrow Perkins KA
- Sanger DJ \rightarrow Griebel G
- Sanna A \rightarrow Motzo C
- Saxon L, Hjelmah P, Hiltunen AJ, Borg S: Effects of flumazenil in the treatment of benzodiazepine withdrawal - a double-blind pilot study 153
- Schindler CW \rightarrow Shoaib M
- Schoffmeier ANM \rightarrow Vanderschuren LJM
- Serra M \rightarrow Motzo C
- Sethy VH \rightarrow Tang AH
- Shoaib M, Baumann MH, Rothman RB, Goldberg SR, Schindler CW: Behavioural and neurochemical characteristics of phen-termine and fenfluramine administered separately and as a mixture in rats 296
- Simansky KJ \rightarrow Lee MD
- Smadja C \rightarrow Valverde O
- Smith JK, Neill JC, Costall B: Post-weaning housing conditions influence the behavioural effects of cocaine and *d*-amphetamine 23
- Soosaar A \rightarrow Volke V
- Southwick SM \rightarrow Krystal JH
- Spampinato U \rightarrow Lucas G
- Standhardt H \rightarrow Deuschle M
- Steen VM \rightarrow Andreassen OA
- Stewart RB \rightarrow Bell SM
- Suzuki T, Mori T, Tsuji M, Misawa M, Onodera K: Interactions between H₁-antagonists and opioids: a drug discrimination study 346
- Svensson L \rightarrow Johansson C
- Tang AH, Franklin SR, Carter DB, Sethy VH, Needham LM, Jacobsen EJ, Von Voigtlander PF: Anxiolytic-like effects of PNU-101017, a partial agonist at the benzodiazepine receptor 255
- Thompson RF \rightarrow Kaneko T
- Thompson SC \rightarrow Bell SM
- Tjon GHK \rightarrow Vanderschuren LJM
- Toledano AY \rightarrow Conley KM
- Tottori K \rightarrow Kikuchi T
- Tsuji M \rightarrow Suzuki T
- Tye SJ \rightarrow Rupniak NMJ
- Umehara K \rightarrow Kudo S
- Uwahodo Y \rightarrow Kikuchi T
- Valverde O, Smadja C, Roques BP, Maldonado R: The attenuation of morphine-conditioned place preference following chronic mild stress is reversed by a CCK_B receptor antagonist 79
- Van der Gugten J \rightarrow Groenink L
- Vanderschuren LJM, Tjon GHK, Nestby P,

- Mulder AH, Schoffelmeer ANM, De Vries TJ: Morphine-induced long-term sensitization to the locomotor effects of morphine and amphetamine depends on the temporal pattern of the pretreatment regimen 115
- Vasar E → Volke V
- Vezina P → Balcells-Olivero M
- Volke V, Soosaar A, Köks S, Bourin M, Männistö PT, Vasar E: 7-Nitroindazole, a nitric oxide synthase inhibitor, has anxiolytic-like properties in exploratory models of anxiety 399
- Volkow ND → Ding Y-S
- Von Voigtlander PF → Tang AH
- Vrijmoed-de Vries M → Andrée B
- Wang G-J → Ding Y-S
- Watson KL → Hernández LL
- Webb E → Krystal JH
- Wilson A → Perkins KA
- Wilson WH → Hege SG
- Woodruff-Pak DS, Hinchliffe RM: Mecamylamine- or scopolamine-induced learning impairment: ameliorated by nefiracetam 130
- Yamaguchi N → Higashima M
- Yamamoto J: Cortical and hippocampal EEG power spectra in animal models of schizophrenia produced with methamphetamine, cocaine, and phencyclidine 379
- Zacny JP → Conley KM
- Zhao J-P → Poland RE
- Zipursky R → Kapur S

Indexed in *Current Contents*,
Psychological Abstracts,
Psyc INFO, *Index Medicus* and in *EMBASE*

Subject index of Volume 131 · 1997

- Abecarnil 101, 123
- Acetylcholine 406
- ACTH 411
- Acute and chronic treatments 180
- β -Adrenergic receptors 307
- Adrenoceptor 371
- Aged rat 49
- Aggression 287
- Aging 130
- Akathisia 108, 174
- Alcohol 287
- Alcohol withdrawal 123
- α_1 -adrenoceptor 49
- Alzheimer's disease 130, 406
- Alzheimer-type dementia 371
- Amisulpride 329
- Amphetamine 115, 167, 230
- d*-Amphetamine 23, 187
- Analgesia 313
- Animal model 321, 379
- Antidepressants 9
- Antipsychotic 239
- Anti-psychotic drugs 174
- Antipsychotic drugs 339
- Anxiety 93, 180, 321, 354, 399
- Anxiolytic 101, 255
- Apomorphine 40
- Attention 140
- Autonomic conditioning 140
- Baclofen 271
- Basolateral area of the amygdala 187
- Befloxatone 180
- Behavior 248
- Behavioural sensitization 115
- Benzodiazepine 64, 101, 255, 394
- Benzodiazepine receptor partial agonist 34
- Benzodiazepines 9, 153, 278, 354
- Betaxolol 307
- β -Blocker 388
- Bout structure 278
- Brain 388
- Butorphanol 313
- Cadmium 248
- β -Carboline 101
- Carteolol hydrochloride 108, 388
- Catalepsy 57, 108
- CCK_B receptor antagonist 79
- D-cycloserine 49
- Central cholinergic nervous system 161
- Cerebral blood flow 220
- Chiral drugs 71
- Chlordiazepoxide 64
- m*-Chlorophenylpiperazine (mCPP) 207
- Chronic unpredictable mild stress 79
- Cigarette smoking 220
- Classical conditioning 161
- CNQX 187
- Cocaine 1, 23, 271, 307, 379
- Cognition 196, 406
- Cognition-enhancing 130
- Cognitive 329
- Cognitive enhancer 371
- Cognitive tasks 101
- Conditioned place preference 1, 79
- Conditioned reinforcement 23
- Conditioned reward 187
- Cortex 379
- Corticosterone 93
- Corticotropin-releasing factor 354
- CP-93,129 264
- CP-94,253 264
- CSF 19
- CYP2D6 genotype 174
- Defensive behaviours 180
- Defensive burying 93
- Delay procedure 161
- Delta opioid antagonist 140
- Delta opioid receptors 140
- Dependence 64
- Depression 79
- Discrete trials procedure 271
- Discrimination 361
- Dopamine 40, 57, 86, 196, 216, 296
- Dopamine D₂ receptor 148
- Dopamine receptors 339
- Dopamine release 34
- Dopamine transporter 71
- Dose versus dose discrimination 307
- Doxepin 19
- Doxepin metabolites 19
- Drug discrimination 296, 307, 346
- Drug interaction 346
- Drug relapse 86
- Drug self-administration 40
- Dyskinesia 239
- EEG power spectra 379
- Elevated plus maze 354
- Environmental enrichment 23
- Ethanol dependence 207
- Ethanol withdrawal 207
- Extrapyramidal side effects 108
- Extrapyramidal symptoms 239
- Eyeblink classical conditioning 130
- Feeding 264
- Fenfluramine 296, 411
- Fixed-interval schedule 40
- Flesinoxan 93
- Flight 180
- Flumazenil 64, 153
- Food-deprivation 1
- Frontal cortex 371
- GABA 271, 394
- GABA_A receptor 255
- GBR 12909 40
- Glycine-B binding site 49
- H₁-antagonist 346
- Haloperidol 57, 86, 148, 216, 329
- Heart rate 140
- Heroin self-administration 86
- Hippocampus 161, 379, 394
- 5-HT_{1A} 93
- Human 313, 329
- Human brain 339
- Humans 9, 101, 153
- Hypnotic 394
- Hypnotics 9
- ICI 118,551 307
- Idazoxan 371
- Imipramine 79
- Individual differences 287
- Internal carotid artery 220
- Intracranial self-administration 187

- Learning 9, 140
- Licking behaviour 278
- Locomotion 230
- Locomotor activity 1, 23, 115, 167
- Long-term treatment 34
- Meal size 264
- Memory 9, 130, 329
- Methamphetamine 379
- 3,4-Methylenedioxymethamphetamine (MDMA) 411
- Methylphenidate 71
- Microdialysis 57, 296
- Microstructure of ingestion 264
- (-)-Propranolol 307
- Moclobemide 180
- Morphine 79, 115, 248, 313
- Motivation 86
- Motor 329
- Motor side-effects 174
- Mouse 399
- Muscarinic receptors 130
- Nadolol 307
- Naltrexone 230
- Naltrindole 140
- Negative symptoms 239
- Neuroleptics 108
- Neurotoxicity 411
- Nicotine 361
- Nicotinic receptors 130
- Nictitating membrane response 161
- Nitric oxide 167
- Nitric oxide synthase 399
- 7-Nitroindazole 399
- Nootropic 130
- Noradrenaline 207
- Nucleus accumbens 34, 187
- 8-OH-DPAT 57
- Operant behavior 40
- Opiate 313
- Opiate-dopamine interactions 230
- Opioid 313, 346
- Opioids 230, 278
- Oral self-administration 287
- ORG 5222 339
- Orienting responses 140
- Pain 313
- Palatability 278
- Palliative therapy 406
- Panic 180
- Panic disorder 321
- Parkinsonism 174
- Partial agonist 255
- Partial benzodiazepine agonists 123
- Pavlovian (classical) conditioning 140
- PD-134,308 79
- Penetrability 388
- Performance 9
- Periaqueductal grey 321
- Peripheral blood flow 220
- PET 339
- Pharmacodynamics 101
- Phencyclidine 167, 379
- Phentermine 296
- Plasma 19
- Plasma levels 148
- Poor metabolizer 174
- Positron emission tomography 71, 339
- Positron Emission Tomography (PET) 148
- Prepulse inhibition 167
- Pretreatment regimen 115
- Prolactin 93, 411
- Psychomotor 313
- Psychomotor skills 101
- Psychomotor stimulant 196, 230
- Psychosis 239
- Quinpirole 40
- Rabbit 140, 379
- [¹¹C]-Raclopride 148
- Radial artery 220
- Rat 1, 23, 167, 287, 388, 399
- Rearing 230
- Recall 9
- Receptor occupancy 148
- 5-HT_{1B} receptors 264
- Recurrent inhibition 394
- Reinforcement 1, 86, 361
- REM sleep deprivation 216
- Repeated drug administration 93
- Reversible monoamine oxidase inhibitors 180
- Reward 1, 23, 79
- Rhesus monkeys 64
- Risk assessment 180
- Ritalin 71
- Ritanserin 57
- Satiety 264
- Schedule-controlled behavior 64
- Schizophrenia 167, 174, 379
- Scopolamine 161
- Second-order schedule 40
- Self-administration 271, 361
- Sensitisation 23
- Sensitization 1, 230, 248
- Serotonergic system 321
- Serotonin 40, 57, 207, 264, 296
- Serotonin (5-HT) 411
- Serotonin receptors 339
- Sex differences 361
- Skill learning 329
- Smoking status 361
- Social isolation 23
- Squirrel monkey 40
- ST 587 49
- Startle 207
- Stereoselectivity 71
- Stress 79, 354
- Striatum 57
- Subjective 313
- Subjective effects 361
- Sublingual administration 339
- Swiss mouse 180
- Tacrine 406
- Tardive dyskinesia 174
- Tertatolol 307
- Time course 115
- Tolerance 361
- Trace procedure 161
- Trazodone 9
- Treatment 123
- Triazolam 9
- Tricyclic antidepressant drugs 321
- Ultrasonics 220
- Ventral subiculum 187
- Vertebral artery 220
- Water maze 49
- Weight-reduction 1
- Withdrawal 153
- Withdrawal syndrome 34
- Yohimbine 207
- Zolpidem 394

